Results from a just-completed Phase 2 clinical trial comparing two dosing regimens (8 mg twice daily vs. 16 mg once daily) of Concert Pharmaceuticals’ (NASDAQ:CNCE) CTP-543 in patients with moderate-to-severe alopecia areata (autoimmune disorder characterized by hair loss) were consistent with a previous mid-stage study evaluating the 8 mg regimen.
No new safety signals were observed.
Additional data will be submitted for presentation at a future medical conference.
Phase 3 studies are next up.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.